chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 81.0
Sex: F
Vaccine: COVID19
Symptoms: Oxygen saturation decreased, Respiratory symptom, Respiratory tract congestion, Viral infection
Clinical narrative: CHIEF COMPLAINT:   Has been having URI symptoms. congestion. some SOB has copd Sore throat. Was @ walkin 12/16 dx viral infection given Abo. No better today Sat low. Upon ems arrival 90% RA Lungs diminished on R Nauseated, given zofran PTA Mid sternal pain CP 3days   HISTORY OF PRESENT ILLNESS:     Has been having URI symptoms congestion shortness of breath and sore throat was at the walk-in on 1216 diagnosed with viral infection not feeling better low O2 sat 90% and also having midsternal chest pain for the past 3 days.  No tearing station the neck chest abdomen pelvis.  No arm pain.  No headache.  No abdominal pain.  No fever or chills.  No other complaints.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Amenorrhoea, Pregnancy test negative
Clinical narrative: Missed period. Over by more than a month. Thrown off cycle. Doctor has to prescribe drugs to bring my period back.
Age: 86.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Chest X-ray normal, Cough, Pelvic pain, SARS-CoV-2 test positive
Clinical narrative: Covid19 breakthrough.  1st vaccine received on 11/12/2021.  86 y/o with PMHx of DM, Epilepsy, DVT presented to ED with 1 day history of vaginal bleeding, pelvic pain and cough.  Room air sat 96%.  CXR with no focal consolidation, afebrile.  Pt on IV abx.
Age: 86.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Vaccine breakthrough infection, Vaginal haemorrhage
Clinical narrative: Covid19 breakthrough.  1st vaccine received on 11/12/2021.  86 y/o with PMHx of DM, Epilepsy, DVT presented to ED with 1 day history of vaginal bleeding, pelvic pain and cough.  Room air sat 96%.  CXR with no focal consolidation, afebrile.  Pt on IV abx.
Age: 61.0
Sex: M
Vaccine: COVID19
Symptoms: Extra dose administered
Clinical narrative: Patient presented to Clinic requesting Moderna Booster. Pt did not have his card. He stated it had been 5-6 months since last dose in series. Pt given Moderna Booster dose 0.25ml IM LDI. No computer access at clinic. Nurse found while documenting the vaccine in system, this was 4th dose. Pt had booster dose on schedule 12/29/2021. No booster needed at this time.
Age: 72.0
Sex: F
Vaccine: COVID19
Symptoms: Injection site bruising, Injection site induration, Injection site nodule, Injection site swelling
Clinical narrative: bruising at injection site, a hard knot, swelling, the size of an orange
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Burning sensation, Insomnia, Mobility decreased, Musculoskeletal stiffness
Clinical narrative: Symptoms: Rash in the vaccinated arm (Burning sensation) was treated with Benadryl, Tylenol and Ibuprofen. Up to this day 02/02/2022 - I have joint pain in my right arm and fingers ( cannot sleep or lay on it) having difficulty moving and gets stiff.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Symptoms: Rash in the vaccinated arm (Burning sensation) was treated with Benadryl, Tylenol and Ibuprofen. Up to this day 02/02/2022 - I have joint pain in my right arm and fingers ( cannot sleep or lay on it) having difficulty moving and gets stiff.
Age: 51.0
Sex: F
Vaccine: UNK
Symptoms: Arthralgia, Musculoskeletal discomfort
Clinical narrative: Significant Bilateral Hip, knee, shoulder, elbow and ankle pain.  Neck Discomfort.  Lower Back Discomfort
Age: 11.0
Sex: F
Vaccine: COVID19
Symptoms: Incorrect dose administered, No adverse event
Clinical narrative: An 11 year old female was given the  age 12+ formula of the Pfizer COVID-19 vaccine in error. No adverse reaction or side effects reported. Patient received a 12+ dose (30mg purple cap Comirnaty formulation) Mother, when notified by phone on discovery of  vaccine administration error and mother reported higher dose was well tolerated with no adverse effects observed.
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Disturbance in attention, Fear, Generalised anxiety disorder, Inappropriate schedule of product administration, Insomnia
Clinical narrative: After the Pfizer vaccination, I felt fine for approximately 2 weeks. However, starting around 2 weeks after the shot I experienced severe generalized anxiety along with occasional bouts of panic attacks. The symptoms also included insomnia, difficulty concentrating, feelings of fear and dread. The symptoms peaked for the next 2 weeks and slowly resolved over the next 4 months. After the first Pfizer vaccine, similar symptoms also occurred but at a much lower level. These symptoms caused me to delay my second shot by 6 months.
Age: 49.0
Sex: M
Vaccine: COVID19
Symptoms: Panic attack, Reaction to previous exposure to any vaccine, Weight decreased
Clinical narrative: After the Pfizer vaccination, I felt fine for approximately 2 weeks. However, starting around 2 weeks after the shot I experienced severe generalized anxiety along with occasional bouts of panic attacks. The symptoms also included insomnia, difficulty concentrating, feelings of fear and dread. The symptoms peaked for the next 2 weeks and slowly resolved over the next 4 months. After the first Pfizer vaccine, similar symptoms also occurred but at a much lower level. These symptoms caused me to delay my second shot by 6 months.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Eye pain, HLA-B*27 positive, Photophobia, Uveitis
Clinical narrative: The night of the night and my left eye was in pain, my left eye. I thought I had an infection so I made an appointment because I though it was a pink eye. They called in some eye drops. 12/31/2021 I had intense pain, even if I closed my left eye or see the light. My dad ended up taking me to the ER and I was referred  with an eye doctor and so I went and saw a doctor and he diagnosed me with uveitis and so they put me on new eye drops and steroids because my eye was attached to my lance or that's what they said. They do believe it was due to the booster. I see my eye doctor again in June/July. I was told that my white blood cells has a marker HLA-B27.
Age: 14.0
Sex: F
Vaccine: COVID19
Symptoms: Incorrect dose administered
Clinical narrative: Child was given a dose of Pfizer for 5-11 years at request of mother, despite age being 14 at time of vaccination.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspepsia, Mechanical urticaria, Pruritus, Temperature intolerance, Urticaria
Clinical narrative: Hives appeared on Dec. 27th, spread all over body, extremely itchy. Itchiness of hands, scalp, ears, eyes). Particularly bad in areas that were rubbed by clothing or were warm. Went to urgent care and got a 6 day taper pack of prednisone, told to follow up with primary care physician if not resolved in 3 days. Not resolved, so visit primary care where I am diagnosed with  dermatographic urticaria and cholinergic urticaria. Taking 1 tablet of 10mg cetirizine daily with 1 tablet of 25 mg hydroxyzine at bedtime. Experienced heartburn on the first day after starting antihistamines which I have never experienced before and, based on my research, appears to be connected (self-treated with tums). Itchiness was much better after starting the antihistamines, but dermatographia and sensitivity to heat remains. Went to a dermatologist who confirmed the diagnosis and recommends up to 4 cetirizine a day with hydroxyzine only as needed as well as steroid creams for the itchiness. No known allergies, nothing new had been added to my environment- I eliminated common allergies from my environment- switched detergents, stopped using fragrances, use sensitive soap, didn't eat eggs, dairy, etc. but did not resolve my symptoms. Was told by both doctors that they are not studying the vaccine but cannot say for sure it was the booster but that it is possible- my primary care had seen someone else with a bad skin reaction ask after their booster. Please take this seriously. I believe in science and the vaccines but this is connected- I have joined a group with as of today 4,000 people and growing that all are pro-vaccine but had the same reaction as me all around a week after receiving the vaccine (mostly Moderna, mostly after the booster) and are sharing visits they've had with immunologists and allergists who are confirming that they are seeing many many people with this reaction after the boosters and that it is starting to be studied.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Urticaria cholinergic
Clinical narrative: Hives appeared on Dec. 27th, spread all over body, extremely itchy. Itchiness of hands, scalp, ears, eyes). Particularly bad in areas that were rubbed by clothing or were warm. Went to urgent care and got a 6 day taper pack of prednisone, told to follow up with primary care physician if not resolved in 3 days. Not resolved, so visit primary care where I am diagnosed with  dermatographic urticaria and cholinergic urticaria. Taking 1 tablet of 10mg cetirizine daily with 1 tablet of 25 mg hydroxyzine at bedtime. Experienced heartburn on the first day after starting antihistamines which I have never experienced before and, based on my research, appears to be connected (self-treated with tums). Itchiness was much better after starting the antihistamines, but dermatographia and sensitivity to heat remains. Went to a dermatologist who confirmed the diagnosis and recommends up to 4 cetirizine a day with hydroxyzine only as needed as well as steroid creams for the itchiness. No known allergies, nothing new had been added to my environment- I eliminated common allergies from my environment- switched detergents, stopped using fragrances, use sensitive soap, didn't eat eggs, dairy, etc. but did not resolve my symptoms. Was told by both doctors that they are not studying the vaccine but cannot say for sure it was the booster but that it is possible- my primary care had seen someone else with a bad skin reaction ask after their booster. Please take this seriously. I believe in science and the vaccines but this is connected- I have joined a group with as of today 4,000 people and growing that all are pro-vaccine but had the same reaction as me all around a week after receiving the vaccine (mostly Moderna, mostly after the booster) and are sharing visits they've had with immunologists and allergists who are confirming that they are seeing many many people with this reaction after the boosters and that it is starting to be studied.
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: Asthenia, Dyspnoea, Dysstasia, Head injury, Hypophagia
Clinical narrative: CHIEF COMPLAINT:   Per pt, had syncopal episode and passed out, hitting head. + LOC. no head/neck/back pain. Neighbor called 911 d/t pt being unable to stand up. SOB and weakness x5 days. Dx with PNA last month and was on abx/steroids with no relief.   HISTORY OF PRESENT ILLNESS:     Patient reports that he is feeling extremely weak had episode where he passed out.  Also reports that he had left leg weakness which improved after a couple of hours.  He denies any left arm weakness. Denies dizziness, numbness, confusion, difficulty speaking, changes in speech or vision. No  fever, chills, diaphoresis, or swelling/pain of lower extremity. Nothing makes better or worse except as previously mentioned. The course is variable. ongoing for 5 days with poor po intake. denies uti sx.
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: Loss of consciousness, Muscular weakness, Pneumonia, Syncope
Clinical narrative: CHIEF COMPLAINT:   Per pt, had syncopal episode and passed out, hitting head. + LOC. no head/neck/back pain. Neighbor called 911 d/t pt being unable to stand up. SOB and weakness x5 days. Dx with PNA last month and was on abx/steroids with no relief.   HISTORY OF PRESENT ILLNESS:     Patient reports that he is feeling extremely weak had episode where he passed out.  Also reports that he had left leg weakness which improved after a couple of hours.  He denies any left arm weakness. Denies dizziness, numbness, confusion, difficulty speaking, changes in speech or vision. No  fever, chills, diaphoresis, or swelling/pain of lower extremity. Nothing makes better or worse except as previously mentioned. The course is variable. ongoing for 5 days with poor po intake. denies uti sx.
Age: 29.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product preparation issue, Underdose
Clinical narrative: A pre-diluted grey-top Pfizer covid vaccine vial (adult) was diluted with 1.8 mL of normal saline. Subsequently, an over-diluted 0.3 mL vaccine was administered to the patient for their booster. The patient was called and notified of this and the CDC recommendation that they are to repeat the dose immediately. The patient stated that they will go to a pharmacy near their home to receive the booster. No adverse events or clinical consequences were reported.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: It was discovered that the vaccine  received was stored in a freezer longer than recommended by the manufacturer.  Per the manufacturer, since the potency of the vaccine cannot be determined, it's unclear of the level of immunity this dose was expected to deliver.  After consulting with our immunization experts, and with the vaccine manufacturer, it's recommended to repeat the dose to ensure full protection.
Age: 67.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Mental status changes, SARS-CoV-2 test positive
Clinical narrative: altered mental status three days after testing positive for COVID.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Headache, Hypersomnia, Nausea, Pain
Clinical narrative: Beginning at about 12am I had light soreness in my arm after my 3rd dose. When I woke up on the 26th at 10am I had fever, chills, sore everywhere, nausea, and headache. I called doctor Wednesday morning and they told me to take OTC  Acetaminophen, I slept for over 16hrs. I took my temperature 100.9 late Wednesday evening. I was not allowed to return to school or work until my temperature was under 100. 12 hours into Thursday the symptoms subsided and I was fine and soreness in arm subsided.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Pyrexia, SARS-CoV-2 test negative
Clinical narrative: Beginning at about 12am I had light soreness in my arm after my 3rd dose. When I woke up on the 26th at 10am I had fever, chills, sore everywhere, nausea, and headache. I called doctor Wednesday morning and they told me to take OTC  Acetaminophen, I slept for over 16hrs. I took my temperature 100.9 late Wednesday evening. I was not allowed to return to school or work until my temperature was under 100. 12 hours into Thursday the symptoms subsided and I was fine and soreness in arm subsided.
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Headache, Pain in extremity
Clinical narrative: Pain left arm for 36 hours. Headache for 36 hours.  Very tired for 48 hours.
Age: 16.0
Sex: F
Vaccine: COVID19
Symptoms: Product preparation issue, Underdose
Clinical narrative: This was the new Grey top vial of Covid 19 vaccine, that does not get diluent added to it, but our MA added Diluent, and then gave the 0.3ml dose.  We discovered it when an RN went to give a dose to another patient and there was a note filled out with the time diluent added and how long the vial would be valid.  Patient had no adverse events while in our office after receiving the vaccine.  We attempted to call the parent but did not receive an answer.   Attempted to call again today 2-22-2022 but still no answer on cell number and home number.  Sent email to rep for the vaccine program, no reply as of yet.
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Alanine aminotransferase normal, Aortic arteriosclerosis, Aspartate aminotransferase increased, Blood alkaline phosphatase normal, Blood bilirubin normal
Clinical narrative: 69 Y male, partially vaccinated (Moderna vaccines x 2, no booster), with history of hypertension, type 2 diabetes, CAD with prior MI s/p PCI, chronic hepatitis C cirrhosis, who presented with progressive dyspnea and was admitted for COVID pneumonia (symptom onset 1/2, COVID positive 1/2). He was transferred to the ICU 1/15 for inhaled nitric oxide.    He completed remdesivir (1/11 to 1/15) and steroid taper (ended 1/25). Hospital course complicated by persistent hypoxemic respiratory failure despite broad spectrum antibiotics (vancomycin, meropenem, caspofungin) and continued trial of inhaled nitric oxide, requiring maximal HFNC since transfer to ICU, then subsequently escalated to BIPAP since 1/28.   His respiratory status continued to decline during the day 1/30 despite on BIPAP, with oxygen saturations dropping as low as 68-70%. Given continued progressive clinical decline on maximal non-invasive interventions, goals of care were again re-discussed with patient and family (via video call) at bedside. He firmly indicated he did not want intubation and declined further escalation of care. Decision was made to transition to comfort care. Patient passed at 11 PM on 1/30/2022. Family was present at bedside.   Complications: None   Diagnoses:   Active Hospital Problems   Diagnosis   ? (Principal) CORONAVIRUS COVID-19 PNEUMONIA   ? ACUTE ON CHRONIC RENAL FAILURE   ? NON-ISCHEMIC MYOCARDIAL INJURY   ? HYPERTENSION   ? DIABETES MELLITUS TYPE 2       DM 2 WO RETINOPATHY Noted: 03/31/2016 Resolved.   Primary Procedures: None   Secondary Procedures: None   Consults: None   Condition on Discharge/Discharge Disposition:  Expired
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Blood chloride normal, Blood cholesterol normal, Blood creatine phosphokinase normal, Blood creatinine increased, Blood glucose normal
Clinical narrative: 69 Y male, partially vaccinated (Moderna vaccines x 2, no booster), with history of hypertension, type 2 diabetes, CAD with prior MI s/p PCI, chronic hepatitis C cirrhosis, who presented with progressive dyspnea and was admitted for COVID pneumonia (symptom onset 1/2, COVID positive 1/2). He was transferred to the ICU 1/15 for inhaled nitric oxide.    He completed remdesivir (1/11 to 1/15) and steroid taper (ended 1/25). Hospital course complicated by persistent hypoxemic respiratory failure despite broad spectrum antibiotics (vancomycin, meropenem, caspofungin) and continued trial of inhaled nitric oxide, requiring maximal HFNC since transfer to ICU, then subsequently escalated to BIPAP since 1/28.   His respiratory status continued to decline during the day 1/30 despite on BIPAP, with oxygen saturations dropping as low as 68-70%. Given continued progressive clinical decline on maximal non-invasive interventions, goals of care were again re-discussed with patient and family (via video call) at bedside. He firmly indicated he did not want intubation and declined further escalation of care. Decision was made to transition to comfort care. Patient passed at 11 PM on 1/30/2022. Family was present at bedside.   Complications: None   Diagnoses:   Active Hospital Problems   Diagnosis   ? (Principal) CORONAVIRUS COVID-19 PNEUMONIA   ? ACUTE ON CHRONIC RENAL FAILURE   ? NON-ISCHEMIC MYOCARDIAL INJURY   ? HYPERTENSION   ? DIABETES MELLITUS TYPE 2       DM 2 WO RETINOPATHY Noted: 03/31/2016 Resolved.   Primary Procedures: None   Secondary Procedures: None   Consults: None   Condition on Discharge/Discharge Disposition:  Expired
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Blood magnesium normal, Blood potassium decreased, Blood sodium decreased, Blood thyroid stimulating hormone decreased, Blood triglycerides increased
Clinical narrative: 69 Y male, partially vaccinated (Moderna vaccines x 2, no booster), with history of hypertension, type 2 diabetes, CAD with prior MI s/p PCI, chronic hepatitis C cirrhosis, who presented with progressive dyspnea and was admitted for COVID pneumonia (symptom onset 1/2, COVID positive 1/2). He was transferred to the ICU 1/15 for inhaled nitric oxide.    He completed remdesivir (1/11 to 1/15) and steroid taper (ended 1/25). Hospital course complicated by persistent hypoxemic respiratory failure despite broad spectrum antibiotics (vancomycin, meropenem, caspofungin) and continued trial of inhaled nitric oxide, requiring maximal HFNC since transfer to ICU, then subsequently escalated to BIPAP since 1/28.   His respiratory status continued to decline during the day 1/30 despite on BIPAP, with oxygen saturations dropping as low as 68-70%. Given continued progressive clinical decline on maximal non-invasive interventions, goals of care were again re-discussed with patient and family (via video call) at bedside. He firmly indicated he did not want intubation and declined further escalation of care. Decision was made to transition to comfort care. Patient passed at 11 PM on 1/30/2022. Family was present at bedside.   Complications: None   Diagnoses:   Active Hospital Problems   Diagnosis   ? (Principal) CORONAVIRUS COVID-19 PNEUMONIA   ? ACUTE ON CHRONIC RENAL FAILURE   ? NON-ISCHEMIC MYOCARDIAL INJURY   ? HYPERTENSION   ? DIABETES MELLITUS TYPE 2       DM 2 WO RETINOPATHY Noted: 03/31/2016 Resolved.   Primary Procedures: None   Secondary Procedures: None   Consults: None   Condition on Discharge/Discharge Disposition:  Expired
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Blood urea increased, Brain natriuretic peptide normal, C-reactive protein increased, COVID-19, COVID-19 pneumonia
Clinical narrative: 69 Y male, partially vaccinated (Moderna vaccines x 2, no booster), with history of hypertension, type 2 diabetes, CAD with prior MI s/p PCI, chronic hepatitis C cirrhosis, who presented with progressive dyspnea and was admitted for COVID pneumonia (symptom onset 1/2, COVID positive 1/2). He was transferred to the ICU 1/15 for inhaled nitric oxide.    He completed remdesivir (1/11 to 1/15) and steroid taper (ended 1/25). Hospital course complicated by persistent hypoxemic respiratory failure despite broad spectrum antibiotics (vancomycin, meropenem, caspofungin) and continued trial of inhaled nitric oxide, requiring maximal HFNC since transfer to ICU, then subsequently escalated to BIPAP since 1/28.   His respiratory status continued to decline during the day 1/30 despite on BIPAP, with oxygen saturations dropping as low as 68-70%. Given continued progressive clinical decline on maximal non-invasive interventions, goals of care were again re-discussed with patient and family (via video call) at bedside. He firmly indicated he did not want intubation and declined further escalation of care. Decision was made to transition to comfort care. Patient passed at 11 PM on 1/30/2022. Family was present at bedside.   Complications: None   Diagnoses:   Active Hospital Problems   Diagnosis   ? (Principal) CORONAVIRUS COVID-19 PNEUMONIA   ? ACUTE ON CHRONIC RENAL FAILURE   ? NON-ISCHEMIC MYOCARDIAL INJURY   ? HYPERTENSION   ? DIABETES MELLITUS TYPE 2       DM 2 WO RETINOPATHY Noted: 03/31/2016 Resolved.   Primary Procedures: None   Secondary Procedures: None   Consults: None   Condition on Discharge/Discharge Disposition:  Expired
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Carbon dioxide decreased, Chest X-ray abnormal, Chronic kidney disease, Coagulation test, Condition aggravated
Clinical narrative: 69 Y male, partially vaccinated (Moderna vaccines x 2, no booster), with history of hypertension, type 2 diabetes, CAD with prior MI s/p PCI, chronic hepatitis C cirrhosis, who presented with progressive dyspnea and was admitted for COVID pneumonia (symptom onset 1/2, COVID positive 1/2). He was transferred to the ICU 1/15 for inhaled nitric oxide.    He completed remdesivir (1/11 to 1/15) and steroid taper (ended 1/25). Hospital course complicated by persistent hypoxemic respiratory failure despite broad spectrum antibiotics (vancomycin, meropenem, caspofungin) and continued trial of inhaled nitric oxide, requiring maximal HFNC since transfer to ICU, then subsequently escalated to BIPAP since 1/28.   His respiratory status continued to decline during the day 1/30 despite on BIPAP, with oxygen saturations dropping as low as 68-70%. Given continued progressive clinical decline on maximal non-invasive interventions, goals of care were again re-discussed with patient and family (via video call) at bedside. He firmly indicated he did not want intubation and declined further escalation of care. Decision was made to transition to comfort care. Patient passed at 11 PM on 1/30/2022. Family was present at bedside.   Complications: None   Diagnoses:   Active Hospital Problems   Diagnosis   ? (Principal) CORONAVIRUS COVID-19 PNEUMONIA   ? ACUTE ON CHRONIC RENAL FAILURE   ? NON-ISCHEMIC MYOCARDIAL INJURY   ? HYPERTENSION   ? DIABETES MELLITUS TYPE 2       DM 2 WO RETINOPATHY Noted: 03/31/2016 Resolved.   Primary Procedures: None   Secondary Procedures: None   Consults: None   Condition on Discharge/Discharge Disposition:  Expired
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Cough, Death, Dyspnoea, Ejection fraction, Electrocardiogram normal
Clinical narrative: 69 Y male, partially vaccinated (Moderna vaccines x 2, no booster), with history of hypertension, type 2 diabetes, CAD with prior MI s/p PCI, chronic hepatitis C cirrhosis, who presented with progressive dyspnea and was admitted for COVID pneumonia (symptom onset 1/2, COVID positive 1/2). He was transferred to the ICU 1/15 for inhaled nitric oxide.    He completed remdesivir (1/11 to 1/15) and steroid taper (ended 1/25). Hospital course complicated by persistent hypoxemic respiratory failure despite broad spectrum antibiotics (vancomycin, meropenem, caspofungin) and continued trial of inhaled nitric oxide, requiring maximal HFNC since transfer to ICU, then subsequently escalated to BIPAP since 1/28.   His respiratory status continued to decline during the day 1/30 despite on BIPAP, with oxygen saturations dropping as low as 68-70%. Given continued progressive clinical decline on maximal non-invasive interventions, goals of care were again re-discussed with patient and family (via video call) at bedside. He firmly indicated he did not want intubation and declined further escalation of care. Decision was made to transition to comfort care. Patient passed at 11 PM on 1/30/2022. Family was present at bedside.   Complications: None   Diagnoses:   Active Hospital Problems   Diagnosis   ? (Principal) CORONAVIRUS COVID-19 PNEUMONIA   ? ACUTE ON CHRONIC RENAL FAILURE   ? NON-ISCHEMIC MYOCARDIAL INJURY   ? HYPERTENSION   ? DIABETES MELLITUS TYPE 2       DM 2 WO RETINOPATHY Noted: 03/31/2016 Resolved.   Primary Procedures: None   Secondary Procedures: None   Consults: None   Condition on Discharge/Discharge Disposition:  Expired
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Eosinophil percentage decreased, Fibrin D dimer increased, Full blood count, Glycosylated haemoglobin increased, Haematocrit normal
Clinical narrative: 69 Y male, partially vaccinated (Moderna vaccines x 2, no booster), with history of hypertension, type 2 diabetes, CAD with prior MI s/p PCI, chronic hepatitis C cirrhosis, who presented with progressive dyspnea and was admitted for COVID pneumonia (symptom onset 1/2, COVID positive 1/2). He was transferred to the ICU 1/15 for inhaled nitric oxide.    He completed remdesivir (1/11 to 1/15) and steroid taper (ended 1/25). Hospital course complicated by persistent hypoxemic respiratory failure despite broad spectrum antibiotics (vancomycin, meropenem, caspofungin) and continued trial of inhaled nitric oxide, requiring maximal HFNC since transfer to ICU, then subsequently escalated to BIPAP since 1/28.   His respiratory status continued to decline during the day 1/30 despite on BIPAP, with oxygen saturations dropping as low as 68-70%. Given continued progressive clinical decline on maximal non-invasive interventions, goals of care were again re-discussed with patient and family (via video call) at bedside. He firmly indicated he did not want intubation and declined further escalation of care. Decision was made to transition to comfort care. Patient passed at 11 PM on 1/30/2022. Family was present at bedside.   Complications: None   Diagnoses:   Active Hospital Problems   Diagnosis   ? (Principal) CORONAVIRUS COVID-19 PNEUMONIA   ? ACUTE ON CHRONIC RENAL FAILURE   ? NON-ISCHEMIC MYOCARDIAL INJURY   ? HYPERTENSION   ? DIABETES MELLITUS TYPE 2       DM 2 WO RETINOPATHY Noted: 03/31/2016 Resolved.   Primary Procedures: None   Secondary Procedures: None   Consults: None   Condition on Discharge/Discharge Disposition:  Expired
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Haemoglobin normal, High density lipoprotein normal, Hypertension, Intensive care, International normalised ratio normal
Clinical narrative: 69 Y male, partially vaccinated (Moderna vaccines x 2, no booster), with history of hypertension, type 2 diabetes, CAD with prior MI s/p PCI, chronic hepatitis C cirrhosis, who presented with progressive dyspnea and was admitted for COVID pneumonia (symptom onset 1/2, COVID positive 1/2). He was transferred to the ICU 1/15 for inhaled nitric oxide.    He completed remdesivir (1/11 to 1/15) and steroid taper (ended 1/25). Hospital course complicated by persistent hypoxemic respiratory failure despite broad spectrum antibiotics (vancomycin, meropenem, caspofungin) and continued trial of inhaled nitric oxide, requiring maximal HFNC since transfer to ICU, then subsequently escalated to BIPAP since 1/28.   His respiratory status continued to decline during the day 1/30 despite on BIPAP, with oxygen saturations dropping as low as 68-70%. Given continued progressive clinical decline on maximal non-invasive interventions, goals of care were again re-discussed with patient and family (via video call) at bedside. He firmly indicated he did not want intubation and declined further escalation of care. Decision was made to transition to comfort care. Patient passed at 11 PM on 1/30/2022. Family was present at bedside.   Complications: None   Diagnoses:   Active Hospital Problems   Diagnosis   ? (Principal) CORONAVIRUS COVID-19 PNEUMONIA   ? ACUTE ON CHRONIC RENAL FAILURE   ? NON-ISCHEMIC MYOCARDIAL INJURY   ? HYPERTENSION   ? DIABETES MELLITUS TYPE 2       DM 2 WO RETINOPATHY Noted: 03/31/2016 Resolved.   Primary Procedures: None   Secondary Procedures: None   Consults: None   Condition on Discharge/Discharge Disposition:  Expired
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Liver function test, Low density lipoprotein normal, Lung consolidation, Lymphocyte percentage decreased, Mean cell volume normal
Clinical narrative: 69 Y male, partially vaccinated (Moderna vaccines x 2, no booster), with history of hypertension, type 2 diabetes, CAD with prior MI s/p PCI, chronic hepatitis C cirrhosis, who presented with progressive dyspnea and was admitted for COVID pneumonia (symptom onset 1/2, COVID positive 1/2). He was transferred to the ICU 1/15 for inhaled nitric oxide.    He completed remdesivir (1/11 to 1/15) and steroid taper (ended 1/25). Hospital course complicated by persistent hypoxemic respiratory failure despite broad spectrum antibiotics (vancomycin, meropenem, caspofungin) and continued trial of inhaled nitric oxide, requiring maximal HFNC since transfer to ICU, then subsequently escalated to BIPAP since 1/28.   His respiratory status continued to decline during the day 1/30 despite on BIPAP, with oxygen saturations dropping as low as 68-70%. Given continued progressive clinical decline on maximal non-invasive interventions, goals of care were again re-discussed with patient and family (via video call) at bedside. He firmly indicated he did not want intubation and declined further escalation of care. Decision was made to transition to comfort care. Patient passed at 11 PM on 1/30/2022. Family was present at bedside.   Complications: None   Diagnoses:   Active Hospital Problems   Diagnosis   ? (Principal) CORONAVIRUS COVID-19 PNEUMONIA   ? ACUTE ON CHRONIC RENAL FAILURE   ? NON-ISCHEMIC MYOCARDIAL INJURY   ? HYPERTENSION   ? DIABETES MELLITUS TYPE 2       DM 2 WO RETINOPATHY Noted: 03/31/2016 Resolved.   Primary Procedures: None   Secondary Procedures: None   Consults: None   Condition on Discharge/Discharge Disposition:  Expired
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Monocyte percentage, Myocardial injury, Neutrophil percentage increased, Oxygen saturation decreased, Platelet count normal
Clinical narrative: 69 Y male, partially vaccinated (Moderna vaccines x 2, no booster), with history of hypertension, type 2 diabetes, CAD with prior MI s/p PCI, chronic hepatitis C cirrhosis, who presented with progressive dyspnea and was admitted for COVID pneumonia (symptom onset 1/2, COVID positive 1/2). He was transferred to the ICU 1/15 for inhaled nitric oxide.    He completed remdesivir (1/11 to 1/15) and steroid taper (ended 1/25). Hospital course complicated by persistent hypoxemic respiratory failure despite broad spectrum antibiotics (vancomycin, meropenem, caspofungin) and continued trial of inhaled nitric oxide, requiring maximal HFNC since transfer to ICU, then subsequently escalated to BIPAP since 1/28.   His respiratory status continued to decline during the day 1/30 despite on BIPAP, with oxygen saturations dropping as low as 68-70%. Given continued progressive clinical decline on maximal non-invasive interventions, goals of care were again re-discussed with patient and family (via video call) at bedside. He firmly indicated he did not want intubation and declined further escalation of care. Decision was made to transition to comfort care. Patient passed at 11 PM on 1/30/2022. Family was present at bedside.   Complications: None   Diagnoses:   Active Hospital Problems   Diagnosis   ? (Principal) CORONAVIRUS COVID-19 PNEUMONIA   ? ACUTE ON CHRONIC RENAL FAILURE   ? NON-ISCHEMIC MYOCARDIAL INJURY   ? HYPERTENSION   ? DIABETES MELLITUS TYPE 2       DM 2 WO RETINOPATHY Noted: 03/31/2016 Resolved.   Primary Procedures: None   Secondary Procedures: None   Consults: None   Condition on Discharge/Discharge Disposition:  Expired
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Positive airway pressure therapy, Prothrombin time prolonged, Respiratory disorder, Respiratory failure, SARS-CoV-2 test positive
Clinical narrative: 69 Y male, partially vaccinated (Moderna vaccines x 2, no booster), with history of hypertension, type 2 diabetes, CAD with prior MI s/p PCI, chronic hepatitis C cirrhosis, who presented with progressive dyspnea and was admitted for COVID pneumonia (symptom onset 1/2, COVID positive 1/2). He was transferred to the ICU 1/15 for inhaled nitric oxide.    He completed remdesivir (1/11 to 1/15) and steroid taper (ended 1/25). Hospital course complicated by persistent hypoxemic respiratory failure despite broad spectrum antibiotics (vancomycin, meropenem, caspofungin) and continued trial of inhaled nitric oxide, requiring maximal HFNC since transfer to ICU, then subsequently escalated to BIPAP since 1/28.   His respiratory status continued to decline during the day 1/30 despite on BIPAP, with oxygen saturations dropping as low as 68-70%. Given continued progressive clinical decline on maximal non-invasive interventions, goals of care were again re-discussed with patient and family (via video call) at bedside. He firmly indicated he did not want intubation and declined further escalation of care. Decision was made to transition to comfort care. Patient passed at 11 PM on 1/30/2022. Family was present at bedside.   Complications: None   Diagnoses:   Active Hospital Problems   Diagnosis   ? (Principal) CORONAVIRUS COVID-19 PNEUMONIA   ? ACUTE ON CHRONIC RENAL FAILURE   ? NON-ISCHEMIC MYOCARDIAL INJURY   ? HYPERTENSION   ? DIABETES MELLITUS TYPE 2       DM 2 WO RETINOPATHY Noted: 03/31/2016 Resolved.   Primary Procedures: None   Secondary Procedures: None   Consults: None   Condition on Discharge/Discharge Disposition:  Expired
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Serum ferritin normal, Troponin, White blood cell count normal
Clinical narrative: 69 Y male, partially vaccinated (Moderna vaccines x 2, no booster), with history of hypertension, type 2 diabetes, CAD with prior MI s/p PCI, chronic hepatitis C cirrhosis, who presented with progressive dyspnea and was admitted for COVID pneumonia (symptom onset 1/2, COVID positive 1/2). He was transferred to the ICU 1/15 for inhaled nitric oxide.    He completed remdesivir (1/11 to 1/15) and steroid taper (ended 1/25). Hospital course complicated by persistent hypoxemic respiratory failure despite broad spectrum antibiotics (vancomycin, meropenem, caspofungin) and continued trial of inhaled nitric oxide, requiring maximal HFNC since transfer to ICU, then subsequently escalated to BIPAP since 1/28.   His respiratory status continued to decline during the day 1/30 despite on BIPAP, with oxygen saturations dropping as low as 68-70%. Given continued progressive clinical decline on maximal non-invasive interventions, goals of care were again re-discussed with patient and family (via video call) at bedside. He firmly indicated he did not want intubation and declined further escalation of care. Decision was made to transition to comfort care. Patient passed at 11 PM on 1/30/2022. Family was present at bedside.   Complications: None   Diagnoses:   Active Hospital Problems   Diagnosis   ? (Principal) CORONAVIRUS COVID-19 PNEUMONIA   ? ACUTE ON CHRONIC RENAL FAILURE   ? NON-ISCHEMIC MYOCARDIAL INJURY   ? HYPERTENSION   ? DIABETES MELLITUS TYPE 2       DM 2 WO RETINOPATHY Noted: 03/31/2016 Resolved.   Primary Procedures: None   Secondary Procedures: None   Consults: None   Condition on Discharge/Discharge Disposition:  Expired
Age: 75.0
Sex: F
Vaccine: COVID19
Symptoms: Computerised tomogram thorax normal, Death, Ultrasound Doppler normal
Clinical narrative: 11/26/2021- Resident passed away on Hospice services with comfort measures in place
Age: 73.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Incorrect dose administered, Malaise, Nasopharyngitis, Pyrexia
Clinical narrative: Patient was given 0.5ml instead of 0.25ml booster 3rd dosage, patient was called on 1/19/2022 and states was sick for 3 days with fever, fatigue, and cold symptoms but nothing else since. Patient was sent a letter informed of  dosage that was given
Age: 85.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Death, Fall, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: This is an instance of breakthrough COVID-19 disease after which death occurred.  The individual was vaccinated with the Moderna product on 01/21/2021 and 02/18/2021. They became symptomatic for COVID-19 disease on 08/24/2021. The individual tested positive for COVID-19 via PCR test on 08/25/2021. They presented to emergency department via ambulance on 08/26/2021 after a fall from bed. Household member reports the individual had been falling frequently as of late. They were admitted to hospital on 08/26/2021 and remained hospitalized until their death on 08/31/2021.
Age: 77.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, Dyspnoea, Hypoxia, SARS-CoV-2 test positive
Clinical narrative: Dyspnea and hypoxia following a positive covid test
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Ankle brachial index, Arrhythmia, Atrial fibrillation, Echocardiogram, Electrocardiogram ambulatory
Clinical narrative: heart arrhythmia a fib
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Imaging procedure, Positron emission tomogram, Ultrasound Doppler
Clinical narrative: heart arrhythmia a fib
Age: 33.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Agranulocytosis, Biopsy bone marrow abnormal, Biopsy liver abnormal, Chills, Computerised tomogram abdomen abnormal
Clinical narrative: 3 days after 2nd dose of Pfizer vaccine  started with high-grade fevers with chills and rigors at night with associated rash neck and under arms,  continued to have fevers for several weeks. diagnosed w/ mono on 9/5/21, completed prednisone, prescribed gabapentin on 9/19/21 for HA, + sob w/ exertion. Presented to ED on 9/20/21 and had low platelet, low white blood cell count.  He reportedly has an enlarged spleen.  His LFTs were elevated.  Hospitalized in October (10/21/21-11/7/21) with fever of unknown origin. Found to have Pancytopenia and suspected hemophagocytic lymphohistiocytosis (HLH).Diagnosed with adult onset Stills disease (AOSD) with MAS in November 2021.   In December he started taking ivermectin, cyprohepadine, glutathione injections and multiple other supplements in attempt to detox COVID vaccine. Patient presented to ED 12/14/21  after outpatient labs drawn yesterday showed significant agranulocytosis WBC 1.6 and thrombocytopenia platelet 22. He continues to have daily fever related to AOSD. He was re-admitted and confirmed diagnosis of refractory HLH via bone marrow biopsy on 1/10/21. HLH complicated by cytopenias, polymicrobial infections resulting in multi-organ failure. Patient discharged with home hospice on 1/27/22 and died on 1/28/22.  His family believes his disease was directly linked to COVID-19 vaccination.
Age: 33.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Cytopenia, Death, Dyspnoea exertional, Haemophagocytic lymphohistiocytosis, Headache
Clinical narrative: 3 days after 2nd dose of Pfizer vaccine  started with high-grade fevers with chills and rigors at night with associated rash neck and under arms,  continued to have fevers for several weeks. diagnosed w/ mono on 9/5/21, completed prednisone, prescribed gabapentin on 9/19/21 for HA, + sob w/ exertion. Presented to ED on 9/20/21 and had low platelet, low white blood cell count.  He reportedly has an enlarged spleen.  His LFTs were elevated.  Hospitalized in October (10/21/21-11/7/21) with fever of unknown origin. Found to have Pancytopenia and suspected hemophagocytic lymphohistiocytosis (HLH).Diagnosed with adult onset Stills disease (AOSD) with MAS in November 2021.   In December he started taking ivermectin, cyprohepadine, glutathione injections and multiple other supplements in attempt to detox COVID vaccine. Patient presented to ED 12/14/21  after outpatient labs drawn yesterday showed significant agranulocytosis WBC 1.6 and thrombocytopenia platelet 22. He continues to have daily fever related to AOSD. He was re-admitted and confirmed diagnosis of refractory HLH via bone marrow biopsy on 1/10/21. HLH complicated by cytopenias, polymicrobial infections resulting in multi-organ failure. Patient discharged with home hospice on 1/27/22 and died on 1/28/22.  His family believes his disease was directly linked to COVID-19 vaccination.
Age: 33.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Infection, Infectious mononucleosis, Laboratory test abnormal, Liver function test increased, Liver injury
Clinical narrative: 3 days after 2nd dose of Pfizer vaccine  started with high-grade fevers with chills and rigors at night with associated rash neck and under arms,  continued to have fevers for several weeks. diagnosed w/ mono on 9/5/21, completed prednisone, prescribed gabapentin on 9/19/21 for HA, + sob w/ exertion. Presented to ED on 9/20/21 and had low platelet, low white blood cell count.  He reportedly has an enlarged spleen.  His LFTs were elevated.  Hospitalized in October (10/21/21-11/7/21) with fever of unknown origin. Found to have Pancytopenia and suspected hemophagocytic lymphohistiocytosis (HLH).Diagnosed with adult onset Stills disease (AOSD) with MAS in November 2021.   In December he started taking ivermectin, cyprohepadine, glutathione injections and multiple other supplements in attempt to detox COVID vaccine. Patient presented to ED 12/14/21  after outpatient labs drawn yesterday showed significant agranulocytosis WBC 1.6 and thrombocytopenia platelet 22. He continues to have daily fever related to AOSD. He was re-admitted and confirmed diagnosis of refractory HLH via bone marrow biopsy on 1/10/21. HLH complicated by cytopenias, polymicrobial infections resulting in multi-organ failure. Patient discharged with home hospice on 1/27/22 and died on 1/28/22.  His family believes his disease was directly linked to COVID-19 vaccination.
Age: 33.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Lumbar puncture normal, Magnetic resonance imaging abnormal, Multiple organ dysfunction syndrome, Pancytopenia, Platelet count decreased
Clinical narrative: 3 days after 2nd dose of Pfizer vaccine  started with high-grade fevers with chills and rigors at night with associated rash neck and under arms,  continued to have fevers for several weeks. diagnosed w/ mono on 9/5/21, completed prednisone, prescribed gabapentin on 9/19/21 for HA, + sob w/ exertion. Presented to ED on 9/20/21 and had low platelet, low white blood cell count.  He reportedly has an enlarged spleen.  His LFTs were elevated.  Hospitalized in October (10/21/21-11/7/21) with fever of unknown origin. Found to have Pancytopenia and suspected hemophagocytic lymphohistiocytosis (HLH).Diagnosed with adult onset Stills disease (AOSD) with MAS in November 2021.   In December he started taking ivermectin, cyprohepadine, glutathione injections and multiple other supplements in attempt to detox COVID vaccine. Patient presented to ED 12/14/21  after outpatient labs drawn yesterday showed significant agranulocytosis WBC 1.6 and thrombocytopenia platelet 22. He continues to have daily fever related to AOSD. He was re-admitted and confirmed diagnosis of refractory HLH via bone marrow biopsy on 1/10/21. HLH complicated by cytopenias, polymicrobial infections resulting in multi-organ failure. Patient discharged with home hospice on 1/27/22 and died on 1/28/22.  His family believes his disease was directly linked to COVID-19 vaccination.
Age: 33.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Pyrexia, Rash, Splenic lesion, Splenomegaly, Still's disease
Clinical narrative: 3 days after 2nd dose of Pfizer vaccine  started with high-grade fevers with chills and rigors at night with associated rash neck and under arms,  continued to have fevers for several weeks. diagnosed w/ mono on 9/5/21, completed prednisone, prescribed gabapentin on 9/19/21 for HA, + sob w/ exertion. Presented to ED on 9/20/21 and had low platelet, low white blood cell count.  He reportedly has an enlarged spleen.  His LFTs were elevated.  Hospitalized in October (10/21/21-11/7/21) with fever of unknown origin. Found to have Pancytopenia and suspected hemophagocytic lymphohistiocytosis (HLH).Diagnosed with adult onset Stills disease (AOSD) with MAS in November 2021.   In December he started taking ivermectin, cyprohepadine, glutathione injections and multiple other supplements in attempt to detox COVID vaccine. Patient presented to ED 12/14/21  after outpatient labs drawn yesterday showed significant agranulocytosis WBC 1.6 and thrombocytopenia platelet 22. He continues to have daily fever related to AOSD. He was re-admitted and confirmed diagnosis of refractory HLH via bone marrow biopsy on 1/10/21. HLH complicated by cytopenias, polymicrobial infections resulting in multi-organ failure. Patient discharged with home hospice on 1/27/22 and died on 1/28/22.  His family believes his disease was directly linked to COVID-19 vaccination.
Age: 33.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Thrombocytopenia, White blood cell count decreased
Clinical narrative: 3 days after 2nd dose of Pfizer vaccine  started with high-grade fevers with chills and rigors at night with associated rash neck and under arms,  continued to have fevers for several weeks. diagnosed w/ mono on 9/5/21, completed prednisone, prescribed gabapentin on 9/19/21 for HA, + sob w/ exertion. Presented to ED on 9/20/21 and had low platelet, low white blood cell count.  He reportedly has an enlarged spleen.  His LFTs were elevated.  Hospitalized in October (10/21/21-11/7/21) with fever of unknown origin. Found to have Pancytopenia and suspected hemophagocytic lymphohistiocytosis (HLH).Diagnosed with adult onset Stills disease (AOSD) with MAS in November 2021.   In December he started taking ivermectin, cyprohepadine, glutathione injections and multiple other supplements in attempt to detox COVID vaccine. Patient presented to ED 12/14/21  after outpatient labs drawn yesterday showed significant agranulocytosis WBC 1.6 and thrombocytopenia platelet 22. He continues to have daily fever related to AOSD. He was re-admitted and confirmed diagnosis of refractory HLH via bone marrow biopsy on 1/10/21. HLH complicated by cytopenias, polymicrobial infections resulting in multi-organ failure. Patient discharged with home hospice on 1/27/22 and died on 1/28/22.  His family believes his disease was directly linked to COVID-19 vaccination.